Type 2 Diabetes Trial, Recruiting NCT05950282 Sponsor: Ali Chappell Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT05950282
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • Both males and females are welcome to participate
  • People from all racial and ethnic backgrounds are welcome
  • People across a wide range of body weights and sizes
  • People with or without a diagnosed condition called Polycystic Ovary Syndrome (PCOS)
  • People who have had specific blood tests completed within the last month, including fasting insulin, HbA1c (a blood sugar measure), a full cholesterol panel, and triglycerides (a type of fat in the blood)
  • The blood tests must have been done through a doctor, an independent laboratory, or using a specific testing kit called the Insara Insulin Testing Kit
  • The blood tests must have been taken after at least 8 hours without eating or drinking (a "fasting" test)
  • People who have complete results for all of the required blood tests listed above

Who may not be able to join:

  • People under 18 years of age
  • People who have another hormonal (endocrine) condition that affects insulin levels, such as a tumour that produces insulin
  • People who have lost more than 5% of their body weight in the past month
  • People who are currently pregnant or breastfeeding
  • People who have had an acute illness or infection in the past 2 weeks
  • People taking medications that are known to significantly affect insulin or blood sugar levels (confirm with trial site, as these may be recorded and considered rather than automatically excluding participation)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ali M Chappell, Insara

Phone: 4092070443

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ali Chappell
Registry
ClinicalTrials.gov
Start date
1 February 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov